Immunome (Nasdaq:IMNM) - Aandelenkoers, Nieuws & Analyse

IMNM Overzicht aandelen

Immunome, Inc., een biotechnologiebedrijf, ontwikkelt doelgerichte kankertherapieën. Meer informatie

IMNM fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 65.1% per jaar groeien

Risicoanalyse

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Immunome, Inc. Concurrenten

Capricor Therapeutics

NasdaqCM:CAPR

US$840.7m

Entrada Therapeutics

NasdaqGM:TRDA

US$674.1m

Verve Therapeutics

NasdaqGS:VERV

US$455.5m

Arcutis Biotherapeutics

NasdaqGS:ARQT

US$1.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Immunome
Historische aandelenkoersen
Huidige aandelenkoers	US$9.91
52 Week Hoogtepunt	US$30.96
52 Week Laag	US$6.93
Bèta	1.82
11 maand verandering	-19.73%
3 maanden verandering	-26.79%
1 Jaar Verandering	23.97%
33 jaar verandering	-42.41%
5 jaar verandering	n/a
Verandering sinds IPO	-26.36%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	IMNM	US Biotechs	US Markt
7D	-23.7%	-10.9%	-2.2%
1Y	24.0%	13.9%	30.1%

Rendement versus industrie: IMNM overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 13.9 % opleverde.

Rendement versus markt: IMNM presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.1 % opleverde.

Prijsvolatiliteit

Is IMNM's price volatile compared to industry and market?
IMNM volatility
IMNM Average Weekly Movement	9.3%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: IMNM heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van IMNM is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2006	105	Clay Siegall	immunome.com

Immunome, Inc., een biotechnologiebedrijf, ontwikkelt doelgerichte kankertherapieën. De klinische activa van het bedrijf bestaan uit AL102, een gammasecretaseremmer die momenteel wordt geëvalueerd in een Fase 3-studie voor de behandeling van tumoren; en de preklinische activa bestaan uit IM-1021, een receptortyrosinekinaseachtige weesreceptor 1 en antilichaam-drugconjugaten, evenals IM-3050, een fibroblastactiveringseiwit gerichte radioligandtherapie; en IM-4320, een anti-IL-38 immuuntherapiekandidaat. Immunome, Inc. werd opgericht in 2006 en is gevestigd in Bothell, Washington.

Immunome, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Immunome zich tot de beurswaarde?
IMNM fundamentele statistieken
Marktkapitalisatie	US$695.32m
Inkomsten(TTM)	-US$305.35m
Inkomsten(TTM)	US$10.13m

61.0x

P/S-verhouding

-2.0x

Koers/Winstverhouding

Is IMNM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IMNM resultatenrekening (TTM)
Inkomsten	US$10.13m
Kosten van inkomsten	US$91.13m
Brutowinst	-US$81.00m
Overige uitgaven	US$224.35m
Inkomsten	-US$305.35m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-4.89
Brutomarge	-799.64%
Nettowinstmarge	-3,014.59%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde IMNM op de lange termijn?

Bekijk historische prestaties en vergelijking

IMNM Overzicht aandelen

Beloningen

Risicoanalyse

Immunome, Inc. Concurrenten

NasdaqCM:CAPR

US$840.7m

NasdaqGM:TRDA

US$674.1m

NasdaqGS:VERV

US$455.5m

NasdaqGS:ARQT

US$1.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors At the European Society for Medical Oncology Congress 2024

Consensus revenue estimates increase by 21%, EPS downgraded

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors At the European Society for Medical Oncology Congress 2024

Consensus revenue estimates increase by 21%, EPS downgraded

Price target decreased by 8.7% to US$30.60

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.

Immunome, Inc. announced that it expects to receive $124.722508 million in funding

No longer forecast to breakeven

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$8.50

High number of new directors

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Forecast to breakeven in 2024

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Immunome GAAP EPS of -$0.74

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1

Immunome gains 34% after preclinical data on COVID-19 antibody

Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Immunome, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target increased to US$33.00

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant

Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth